ArticleJCEM case reports2026
Noninsulinoma Hyperinsulinemic Hypoglycemia Syndrome Emerging Post-Nissen Fundoplication.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoglycemia presents a rare and complex diagnostic challenge, particularly in individuals with a history of upper gastrointestinal procedures such as Nissen fundoplication. Given the overlapping clinical presentations, it is essential to distinguish between insulinoma and noninsulinoma hyperinsulinemic hypoglycemia syndrome. In this report, we outline the case of a 54-year-old man with a history of Nissen fundoplication who presented with recurrent, severe hypoglycemic episodes, often occurring without warning, and significantly impairing his quality of life. Continuous glucose monitoring (CGM) revealed frequent hypoglycemia in both the postprandial and fasting states. Diagnostic evaluation excluded insulinoma but confirmed inappropriate endogenous insulin secretion, consistent with nesidioblastosis. The patient was successfully managed with diazoxide, which significantly reduced the frequency and severity of hypoglycemic events. This case underscores the importance of considering endogenous hyperinsulinemia in postfundoplication patients with unexplained hypoglycemia. It also highlights the utility of CGM and pharmacologic therapy in improving safety, enabling individualized care, and reducing the risk of hypoglycemia unawareness and its associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.